Coming back to post #3, because the follow-up matters more than the original answer.
Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1 agonist requires insulin dose reduction and close monitoring for hypoglycemia. This is manageable with attention.
I would want a second opinion before relying on that.